Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast UNLOXCYT Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    UNLOXCYT Coverage for Cutaneous Squamous Cell Carcinoma

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage for physician-administered intravenous UNLOXCYT (cosibelimab-ipdl) in adults with metastatic or locally advanced cutaneous squamous cell carcinoma. It specifies clinical eligibility, dosing, administration settings, coding, authorization duration, and monitoring considerations.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyUNLOXCYT Coverage for Cutaneous Squamous Cell Carcinoma
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for physician-administered UNLOXCYT and document that all coverage criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1200 mgMaximum dose
    6 monthsInitial authorization
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Reauthorization
    ≥18 yearsMinimum age
    300 mg/5 mLVial presentation

    Coverage Criteria

    Initial Approval Criteria

    Initial approval is covered when ALL of the following criteria are met:

    ALL of the following

    • Physician-administered intravenous infusion in an office or hospital outpatient department (HOPD). The medication cannot be self-administered.
    • Diagnosis of metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC).
    • Patient is not a candidate for curative surgery or curative radiation.
    • Unloxcyt is used as a single agent.
    • Prescribed by or in consultation with an oncologist.
    • Patient is 18 years of age or older.≥ 18 years
    • Individual has not received another anti-PD-1 or anti-PD-L1 agent, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant.
    • Individual has an ECOG performance status of 0–1.
    • Individual does not have uncontrolled or significant cardiovascular disease (CVD).
    • Individual does not have an infection with HIV, hepatitis B, or hepatitis C.
    • Dose does not exceed 1,200 mg by intravenous infusion every 3 weeks.≤ 1,200 mg IV every 3 weeks

    Coverage is limited to adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who meet all approval criteria above. Unloxcyt must be administered by intravenous infusion in an office or hospital outpatient department and is not covered for self-administration; dosing is limited to 1,200 mg every 3 weeks.

    Patients must not have received another anti-PD-1 or anti-PD-L1 agent or other therapy targeting T-cell costimulation or immune checkpoint pathways, must not be receiving systemic immunosuppressive therapy for an autoimmune disease or chronic condition, and must not have uncontrolled or significant cardiovascular disease or HIV, hepatitis B, or hepatitis C infection.

    Coding and Treatment Parameters

    NDC CodesNDC
    70095-130-0110-digit NDC
    70095-0130-0111-digit NDC
    HCPCS CodeHCPCSCovered
    J9275Injection, cosibelimab-ipdl, 2 mg
    CPT Procedural CodeCPTCovered
    96413Chemotherapy infusion, up to one hour
    UNLOXCYT Dose
    Standard regimen1200 mg by intravenous infusion every 3 weeks
    Maximum doseDose must not exceed 1200 mg
    Infusion durationInfusion time is 60 minutes
    ECOG Performance Status
    Required rangeECOG Performance Status must be 0-1
    ECOG 0Fully active; can carry out all normal activities without restriction
    ECOG 1

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization and Authorization Duration

    Prior authorization is required for Unloxcyt (cosibelimab-ipdl) injection. Authorization is issued for an initial six-month period and may be renewed for 12 months when continued coverage criteria are met.

    • Initial authorization: 6 months.
    • Reauthorization: 12 months.
    Documentation Required

    Clinical and Treatment Documentation

    Submit clinical and treatment documentation supporting the diagnosis, disease extent, treatment setting, and eligibility for Unloxcyt. Documentation must establish that treatment is being administered as an appropriate single-agent therapy and include the relevant patient risk and treatment details.

    • Diagnosis of metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC).

    Clinical Background

    UNLOXCYT (cosibelimab-ipdl) is a programmed death ligand-1 (PD-L1) blocking antibody used in adults with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Treatment is administered by intravenous infusion and continues until disease progression or unacceptable toxicity. Potential risks include immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity.

    Definitions

    ECOG Performance Status
    PurposeA scale used in cancer care to measure functional ability and overall well-being
    ECOG 0Fully active; can carry out all normal activities without restriction
    ECOG 1Restricted in physically strenuous activity but can do light or sedentary work, such as light housework or office work
    Higher scoresHigher scores indicate progressively greater functional limitation; 5 means deceased
    UNLOXCYT
    Drug nameUNLOXCYT (cosibelimab-ipdl)
    Drug class

    Initial Therapy

    Initial Therapy Criteria

    Initial coverage requires physician-administered intravenous treatment and all of the following cutaneous squamous cell carcinoma criteria.

    Initial therapy

    • UNLOXCYT is administered as a physician-administered intravenous infusion in the office or hospital outpatient department and cannot be self-administered.
    • The patient has metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma.
    • The patient is not a candidate for curative surgery or curative radiation.
    • UNLOXCYT is used as a single agent.

    Reauthorization

    Continuation Criteria

    Reauthorization is available when the following requirement is met.

    Reauthorization

    • Reauthorization is available for 12 months.12 months
    • Dose approval follows FDA-approved labeling or accepted standards of medical practice.

    Quantity Limits

    UNLOXCYT (cosibelimab-ipdl)
    Dose per infusion1200 mg
    Administration routeIntravenous infusion
    Administration intervalEvery 3 weeks

    Administration Site Requirements

    Billing Rule

    Office administration required

    Administer UNLOXCYT as a physician-administered IV infusion in an office setting. The treatment cannot be self-administered.

    Billing Rule

    Hospital outpatient administration required

    Administer UNLOXCYT as a physician-administered IV infusion in a hospital outpatient department. The treatment cannot be self-administered.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyUNLOXCYT Coverage for Cutaneous Squamous Cell Carcinoma
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for physician-administered UNLOXCYT and document that all coverage criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Treatment ParametersProvider Requirements and AuthorizationClinical BackgroundDefinitionsInitial TherapyReauthorizationQuantity LimitsAdministration Site Requirements
    Restricted in physically strenuous activity but able to do light or sedentary work
    Minimum Patient Age
    Minimum age18 years
    Eligible populationAdults
    Coverage requirementThe patient must be at least 18 years old
  1. Documentation that the patient is not a candidate for curative surgery or curative radiation.
  2. Physician-administered IV infusion in an office or hospital outpatient department (HOPD); the drug cannot be self-administered.
  3. Single-agent use, prescribed by or in consultation with an oncologist.
  4. Patient age, ECOG performance status, prior anti-PD-1/PD-L1 or other immune checkpoint therapy, autoimmune disease and systemic immunosuppressant use, cardiovascular disease, HIV/hepatitis status, and planned dose and schedule must be documented.
  5. Denial Risk

    Clinical Eligibility Requirements

    Coverage is at risk when the patient does not meet the required clinical eligibility criteria for Unloxcyt treatment.

    • Adult patient age 18 years or older.
    • Diagnosis of mCSCC or laCSCC, with the patient not a candidate for curative surgery or curative radiation.
    • ECOG performance status of 0–1.
    • Use as a single agent; the patient must not have received another anti-PD-1, anti-PD-L1, or other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
    • The patient must not be receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
    • The patient must not have uncontrolled or significant cardiovascular disease or infection with HIV, hepatitis B, or hepatitis C.
    • Dose must not exceed 1,200 mg IV every 3 weeks.
    Billing Rule

    Administration and Prescriber Requirements

    Unloxcyt must be administered by a physician as an IV infusion in an office or HOPD and cannot be self-administered. The prescriber must be an oncologist or prescribe in consultation with an oncologist.

    • Physician-administered IV infusion only.
    • Permitted settings: in-office or HOPD.
    • Prescribed by or in consultation with an oncologist.
    • Maximum dose: 1,200 mg IV every 3 weeks.
    Note

    Applicable External Coverage Requirement

    Dose and treatment must comply with the FDA-approved labeling or accepted standards of medical practice and must follow Medicare Local Coverage Determination (LCD) L37205, Chemotherapy Drugs and their Adjuncts.

    • Follow LCD L37205 - Chemotherapy Drugs and their Adjuncts.
    • Use dosing consistent with FDA-approved labeling or accepted standards of medical practice.
    Programmed death ligand-1 (PD-L1) blocking antibody
    Covered useUsed for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation
    UNLOXCYT is prescribed by or used in consultation with an oncologist.
  6. The patient is at least 18 years old.>= 18 years
  7. The patient has not received another anti-PD-1 agent, anti-PD-L1 agent, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  8. The patient is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant.
  9. The patient has an ECOG performance status of 0-1.ECOG 0-1
  10. The patient does not have uncontrolled or significant cardiovascular disease.
  11. The patient does not have HIV, hepatitis B, or hepatitis C infection.
  12. The dose does not exceed 1200 mg by intravenous infusion every 3 weeks.1200 mg IV every 3 weeks maximum